---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-035853"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-09-08T12:35:36+00:00"
generated_at: "2026-09-08T12:40:09.178357+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech raises up to $22.55M in PIPE led by Nant; Soon-Shiong to join board

## Summary
- PIPE raises up to $22.55M: $11.55M initial closing at $0.2825/unit, plus $11M milestone (Nant $10M, AB Group $1M) upon Phase 3 protocol submission.
- Nant Capital led; Dr. Patrick Soon-Shiong to join board; Nant gets right to designate 2 directors while owning ≥15%.
- Proceeds to repay debt and fund development; PDS0301 Phase 2 data in MSS/pMMR mCRC showed 80% survival at 24 months.
- Company grants NantWorks 1-year exclusive option to negotiate license for PDS0101; board expands from 6 to 8.
- Common warrants exercisable at $0.22/share for 1 year; pre-funded warrants at $0.00033; 19.9% beneficial ownership cap.

## SEC filing metadata
- accession: 0001140361-26-035853
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-09-08T12:35:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126035853/0001140361-26-035853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126035853/ef20081705_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-035853
- JSON: https://secwatch.observer/filing/0001140361-26-035853.json
- Plain text: https://secwatch.observer/filing/0001140361-26-035853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.